- Home
- MGNX vs BTMD Comparison
MGNX vs BTMD Comparison
Compare MGNX & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- BTMD
- Stock Information
- Founded
- MGNX 2000
- BTMD 2012
- Country
- MGNX United States
- BTMD United States
- Employees
- MGNX N/A
- BTMD N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- MGNX Health Care
- BTMD Health Care
- Exchange
- MGNX Nasdaq
- BTMD Nasdaq
- Market Cap
- MGNX 99.7M
- BTMD 90.0M
- IPO Year
- MGNX 2013
- BTMD N/A
- Fundamental
- Price
- MGNX $1.86
- BTMD $2.74
- Analyst Decision
- MGNX Hold
- BTMD Buy
- Analyst Count
- MGNX 6
- BTMD 2
- Target Price
- MGNX $3.20
- BTMD $6.00
- AVG Volume (30 Days)
- MGNX 726.3K
- BTMD 104.4K
- Earning Date
- MGNX 11-04-2025
- BTMD 11-05-2025
- Dividend Yield
- MGNX N/A
- BTMD N/A
- EPS Growth
- MGNX N/A
- BTMD 642.53
- EPS
- MGNX N/A
- BTMD 0.88
- Revenue
- MGNX $165,495,000.00
- BTMD $199,073,000.00
- Revenue This Year
- MGNX N/A
- BTMD N/A
- Revenue Next Year
- MGNX N/A
- BTMD $4.85
- P/E Ratio
- MGNX N/A
- BTMD $3.11
- Revenue Growth
- MGNX 303.47
- BTMD 6.32
- 52 Week Low
- MGNX $0.99
- BTMD $2.71
- 52 Week High
- MGNX $5.10
- BTMD $6.98
- Technical
- Relative Strength Index (RSI)
- MGNX 55.15
- BTMD 38.36
- Support Level
- MGNX $1.82
- BTMD $2.73
- Resistance Level
- MGNX $2.15
- BTMD $3.01
- Average True Range (ATR)
- MGNX 0.13
- BTMD 0.13
- MACD
- MGNX 0.01
- BTMD -0.00
- Stochastic Oscillator
- MGNX 49.15
- BTMD 7.24
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.